Dec 28 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved TG Therapeutics Inc's drug for patients with relapsing forms of multiple sclerosis, pitting it against rivals from Roche and Novartis, according to the health regulator's website. (Reporting by Sriparna Roy, Khushi Mandowara and Raghav Mahobe in Bengaluru; Editing by Anil D'Silva)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.51 USD | +1.98% | +23.95% | -3.34% |
01/05 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
01/05 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
221.4 USD | +1.80% | +2.75% | 31.67B | ||
218.5 CHF | +0.55% | -1.13% | 194B | ||
88.1 CHF | +0.15% | -1.56% | 198B | ||
16.51 USD | +1.98% | +23.95% | 2.35B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.34% | 2.35B | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- U.S. FDA approves TG Therapeutics' multiple sclerosis drug